Chemotherapy and thrombosis in gynecologic malignancy

Clinical and Applied Thrombosis/Hemostasis

Volumn 5, Issue 2, 1999, Pages 92-104

  Von Tempelhoff, Georg Friedrich ^a,b   Pollow, Kunhard ^a   Schneider, Dirk ^a   Heilmann, Lothar ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Gesundheits und Pflegezentrum Russelsheim   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; CERTOPARIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METHOTREXATE; TAMOXIFEN; TOREMIFENE; VINCRISTINE; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD RHEOLOGY; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CHEMOPROPHYLAXIS; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG INDICATION; DRUG MEGADOSE; GYNECOLOGIC CANCER; HIGH RISK POPULATION; HUMAN; HYPERCOAGULABILITY; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032939093     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969900500204     Document Type: Review

References (110)

1. Heilmann L, von Tempelhoff G-F, Schneider DM. Prevention of thrombosis in gynecological malignancy. Clin Appl Thromb Hemost 1998;4:153.
2. Clahsen PC, Cornelis JH, van der Velde JPJ, et al. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: A European Organization for Research and Treatment of Cancer Breast Cooperative Group Study. J Clin Oncol 1994;12:1266.
3. von Tempelhoff G-F, Wolf H, Herrle B, et al. Low molecular weight heparin. Clin Appl Thromb Hemost 1996;2:292.
4. Heilmann L, von Tempelhoff G-F, Herrle B, et al. Low-Dose Heparin versus niedermolekulares Heparin zur Thromboseprophylaxe in der operativen gynäkologischen Onkologie. Geburtsh und Frauenheilk 1997;57:1.
5. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286.
6. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404.
7. Pemberton KD, Melissari E, Kakkar VV. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis, Blood Coagul Fibrinolysis 1993;4:935.
8. Goldhaber SZ. Epidemiology of pulmonary embolie and deep vein thrombosis. In: Bloom AL, Forbes ChD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis. New York: Churchill Livingston, 1994:1327.
9. Ludwig H. Klinisch - experimentelle Untersuchungen zur thromobotischen Diathese bei der gynäkologischen Radiumbehandlung. Geburtsh Frauenhlk 1962;22:1121.
10. Graf AH, Graf B, Riedl B, et al. Risiko und Prophylaxe thromboembolischer Komplikationen beim Zervix - und Korpuskarzinom. Gynäkol Geburtshilf Rundsch 1994;34(suppl 1):95.
11. Graf AH, Graf B, Traun H, et al. Risiko und Prophylaxe thromboembolischer Komplikationen bei gynäkologischen Malignomen. Gynäkol Geburtshilf Rundsch 1996;36:37
12. Saeger W, Genzkow M. Venous thromboses and pulmonary embolisms in post-mortem series: probable causes by correlation of clinical data and basic diseases. Pathol Res Pract 1994;190:394.
13. Berek JS, Hacker NF. Practical gynecologic oncology. Baltimore, Philadelphia, Hong Kong: Williams & Wilkins, 1994:377.
14. Fowkes FGR, Pell JP, Donnan PT, et al. Sex differences in susceptibility to etiologic factors for peripheral atherosclerosis. Arterioscler Thromb 1994;14:862.
15. Semeraro N, Montemurro P, Conese M, et al. Procoagulant activity of mononuclear phagocytes from different anatomical sites in patients with gynecologic malignancies. Int J Cancer 1990;45: 251.
16. Mellor H, Taylor I, Roath S, Francis JL. Whole blood procoagulant activity in breast and colorectal cancer. J Clin Pathol 1989;42:489.
17. Moradi MM, Carson LF, Weinberg B, et al. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor alpha in patients with ovarian epithelial cancer. Cancer 1993;72:2433.
18. Edwards RL, Silver J, Rickles FR. Human tumor procoagulants. Registry of the subcommittee on haemostasis and malignancy of the scientific and standardization committee, international society on thrombosis and haemoMasis. Thromb Haemost 1993;69:205.
19. Zacharski LR, Memoli VA, Ornstein DL, et al. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst 1993;85:1225.
20. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996;2:209.
21. Zhang Y, Deng Y, Luther T, et al. Tissue Factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94:1320.
22. Constantino V, Zacharski LR, Memoli VA, et al. Occurrence of compounds of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue. Cancer Res 1991;1:354.
23. Pujade-Lauraine E, Lu H, Mirshahi S, et al. The plasminogen-activation system in ovarian tumors. Int J Cancer 1993;55:27.
24. Schmalfeldt B, Kuhn W, Reuning U, et al. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptors and inhibitors type 1 and 2. Cancer Res 1995;55:3958.
25. Casslén B, Bossmar T, Lecander I, Astedt B. Plasminogen activators and plasminogen activator inhibitors in blood and tumor fluids of patients with ovarian cancer. Eur J Cancer 1994;30A:1209.
26. von Tempelhoff G-F, Heilmann L, Dietrich M, et al. Plasmatic plasminogen activator inhibitor activity in patients with primary breast cancer. Thromb Haemost 1997;77:606.
27. Uchiyama T, Matsumoto M, Kobayashi N. Studies on the pathogenesis of coagulopathy in patients with arterial thromboembolism and malignancy. Thromb Res 1990;59:955.
28. Nielsen HJ, Pappot H, Christensen IJ, et al. Association between plasma PAI-I levels and survival in patients with colorectal cancer. BMJ 1997;316:829.
29. de Jong E, Knot EAR, Iburg AHC, et al. Increased plasminogen activator inhibitor activator inhibition levels in malignancy. Thromb Haemost 1987;57:140.
30. Newland JR, Haire WD. Elevated plasminogen activator inhibitor levels found in patients with malignant conditions. Am J Clin Pathol 1991;96:602.
31. Mahadevan V, Hart IR. Metastasis and angiogenesis. Rev Oncol 1990;3:97.
32. Mueller-Berghaus G. Physiologie des Hämostasesystems. In: Müller-Berghaus C, ed. Transfusionsmedizin Berlin, Heidelberg, New York: Springer, 1996:45.
33. Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost 1996;75:536.
34. Bick RL, Baker WF. Antiphospholipid and thrombosis syndromes. Semin Thromb Hemost 1994;20:3.
35. Zuckerman E, Toubi E. Golan TD, et al. Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer 1995;72:447.
36. Falanga A, Ofosu FA, Cortelazzo F, et al. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br J Haematol 1993;85:745.
37. Iversen LH, Okholm M, Thorlacius-Ussing O. Pre- and postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant colorectal disease - a preliminary study. Thromb Haemost 1996;76:523.
38. Gadducci A, Baicchi U, Marrai R, et al. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gynecol Oncol 1996;60:197.
39. von Tempelhoff G-F, Niemann F, Schneider D, et al. Gerinnungsuntersuchungen und Thromboseinzidenz während der Cisplatin/ Epirubicin/Cyclophosphamid Chemotherapy beim Ovarialkarzinom. Geburtsh Frauenhlk 1997;57:595.
40. von Tempelhoff G-F, Dietrich M, Niemann F, et al. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997;77:456.
41. von Tempelhoff G-F. Changes of hemorrheology and clotting in different gynecologic malignancies. Clin Hemorheol 1995;15: 261.
42. von Tempelhoff G-F, Heilmann L. Hommel G. et al. Hyperviscosity syndrome in ovarian malignancy. Cancer 1998;82:1104
43. Rampling MW. Whittingstall MW. Linderkamp O. The effect fibrinogen and its plasmin degradation products on the rhcoj of erythrocyte suspension. Clin Heinorheol 1984:4:533.
44. Löwe GDO. Blood rheology and venous thrombosis. Cr Heinorheol 1984;4:571.
45. Thomas DP. Pathogenesis of venous thrombosis. In: Colman RW Hirsh J. Marder VJ. Salzman EW. eds. Hemoatasis and Thrombosis. Philadelphia: J.B. Lippincott, 1982:820.
46. Mercke CE. Anemia in patients with solid tumors and the rate of erythrocyte deformability. Br J Cancer 1981:44:425.
47. Balendra R, Rumley A, Orr M, et al. Blood lipids. coagulation fibrinolysis and rheology in spontaneous proven deep vein thrombosis [Abstract]. Br J Haematol 1991:79(suppl 1):83.
48. von Tempelhoff G-F. Heilmann L. Berg C. et al. Comparison of pretreatment clotting estimations in 428 patients with gynecologic malignancy [Abstract]. Throinb Haemost 1997;77(suppl):123.
49. McCulloch P, Nieuwenhuixen W. Douglas J, et al. Coagulation disturbance in cancer of the breast and colon measured with specific monoclonal antibody enzyme immunoassay for fibrin-fibrinogen degradation products. Haemostasis 1990;20:73.
50. Neises M, Schäfer T, Strittmann H-J, et al. D-dimer und Plavminogen Aktivator vom Urokinasetyp: Eigene Erfahrungen be, Mammakarzinomen. Geburtsh Fnntenhlk 1993:53:455.
51. von Tempelhoff G-F, Dietrich M, Hommel G, Heilmann L. Blond coagulation during adjuvant epirubicin/cyclophos-phamide che-motherapy in patients with primary operable breast cancer. J Clin Oncol 1996:14:2560.
52. Mitter CG, Zielinski CC. Plasma levels of D-dimer: A crosslinked fibrin-degradation product in female breast cancer. J Cancer Res Clin Oncol 1990:117:259.
53. Prins MH, Turpie AGG. Diagnosis and treatment of venou-thromboembolism. In: Bloom AL. Forbes ChD, Thomas DP. Tuddenham EGD, eds. Haemostasis and Thrombosis. New Yort Churchill Livingstone. 1994:1381.
54. Weiss RB, Tormey DC, Holland F. Weinberg VE. Venous thrombosis during multimodal treatment of primary breast carcinoma Cancer Treat Rex 1981:65:677.
55. Bonadonna G, Gianni L, Santoro A. et al. Drugs ten years later epirubicin. Ann Oncol 1993;4:359.
56. Rifkin SE, Green S, Metch B. Adjuvant CMFVP versus tamuxi-fen concurrent CMFVP and tamoxifen for posttnenopausal node positive estrogen receptor positive breast cancer patients: a South-west Oncology Group Study. J Clin Oncol 1994:12:2078.
57. Bonadonna G, Valagussa P. The contribution of medicine to the primary treatment of breast cancer. Cancer Res 1988:48:2314.
58. Levine M, Hirsh J. Gent M, et al. Double-blind randomised tria' of very-low-dose warfarin for prevention of thromboemholism IE stage IV breast cancer. Lancet 1994:343:886.
59. Falanga A, Levine MN, Consonni R, et al. The effect of very low-dose warfarin on markers of hypercoagulation in metaslatk breast cancer: results from a randomized trial. Thromb Haemostasis 1998:79:23.
60. Goodnough LT, Saito H, Manni A, et al. Increased incidence at thromboembolism in stage IV breast cancer patients treated with five drug chemotherapy regimen. Cancer 1984;54:1264.
61. Manni A, Trujillo JE, Pearson OH. Therapy and chemotherapy for metastatic breast cancer: effects on survival. Cancer Treat Res 1980:64:111.
62. Wall JG, Weiss RB. Norton L. Arterial thrombosis associate with adjuvant chemotherapy for breast cancer: a cancer and leukemia group B study. Am J Med 1989;87:501.
63. Pritchard KI, Paterson AHG, Paul NA. et al. Increased thrombosis embolie complications with concurrent tamoxifen and chenu1 therapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol 1996:14:2731.
64. Fisher B, Redmond C. Legault-Poisson D. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive node breast cancer patients aged 50 yeas and older with tumours responsive to tamoxifen: Results from the national surgical adjuvant breast and bowel project B16. J Clin Oncol 1990;8:1005.
65. Rober-Soivinelli K. Farber LV. Lundberg WB. et al. Thrombo-mbolic disease in breast cancer patients receiving chemo/ hormonal therapy [Abstract], Proc Asco 1986:5:64.
66. Canney PA, Wilkinson PM. Pulmonary embolism in patients receiving chemotherapy for advanced ovarian cancer. Eur J Cancer Clin Oncol 1985:21:585.
67. Fisher B. Constatino J, Redmond C. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node nega-tive breaM cancer who have estlogen-receptor positive tumours. N Engl J Med 1989:320:479.
68. Love RK, Surawicz TS, Williams EC. Anti thrombin III level, fibrinoucii level, and platelet count changes with adjuvant tamoxifen therapy. Arch Intern Med 1992;152:317.
69. Mamby CC, Love RR, Feyzi JM. Protein S and protein C level changes with adjuvant tamoxifen therapy in postmenopausal women. Breast Cancer Res Treat 1994:30:311.
70. McDonald CC. Alexancer FE, Whyte BW, et al. for the Scottish cancer (nais breast group. Cardiac and vascular morbidity in women receiving tamoxifen for breast cancer in a randomised trial. BMI 1995;311:977.
71. Hayes DF, van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmeno-pausal patients with metastatic breast cancer. J Clin Oncol 1995; 13:2556.
72. Beex L. Pieters G, Smals A. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat Res 1981;65:179.
73. Lipton A, Harvey HA, Hamilton RW. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Res 1984;68:887.
74. Castiglione-Gertsch M, Pampallona S, Varini M, et al. Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate. Ann Oncol 1994;4:735.
75. Gershanovich M, Garin A, Baltina D, et al. Eastern European Study Group. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with adjuvant breast cancer. Breast Cancer Res Treat 1997;46:251.
76. Pannuli F. Martoni A, Citent G, et al. Adjuvant therapy for op-erable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in pre-menopausal patients. Eur J Cancer Clin Oncol 1988;24:423.
77. Basten G. Michel RT. Hochdosierte Gestagentherapie mit Me-drox\ progesteronacetat (HD-MPA) beim metastasierenden Mammkarzinom. Med Welt 1984:34:61.
78. Follow K, Kreienberg R, Juchem M, Hoffmann G. Hochdosierte Medioxyprogesteronacetat (MPA)-Therapie beim fortgeschrit-tenen Mammakarzinom unter besondere Berücksichtigung der MPA Serumspiegel. Tumordiagn u Ther 1993;14:49.
79. Delia Cuna GR, Calciati A, Strada MRB, et al. High dose me-drox \progesterone acetate (MPA) treatment in metastatic carci-noma of the breast: a dose-response evaluation. Tumori 1978:64: 143.
80. Samonis G, Margioris AN, Bafaloukos D, Razis DV. Prospective randomized study of aminogluthethimide (AG) versus medroxy-progcsterone acetate (MPA) versus AG + MPA in generalized brea-t cancer. Oncology 1994;51:411.
81. Japan Advanced Breast Cancer Study Group and Japan Clinical Oncology Group. Effects of chemoendocrine therapy on the co-agulation-fibrinolytic systems in patients with advanced breast cancer. Jpn J Cancer Res 1993;84:455.
82. Abrains JS, Gutheil J, Aisner J. Potential applications of high-dosc megestrol acetate in breast cancer. Oncology 1992;49(suppl 2):12.
83. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromataseinhibitor, vs. Megestrol acetate in postmeno-paiKil women with advanced breast cancer: results of overview anahsis of two phase II trials. J Clin Oncol 1996:14:2000.
84. Parnes HL, Abrams JS, Techekmcdyain S, et al. A phase I/II study of high-dose megestrol acetate in the treatment of meta-static breast cancer. Breast Cancer Res Treat 1991:18:171.
85. Tchekmedyian S, Tait N, Abrams J, Aisner J. High-dose Meges-trol acetate in the treatment of advanced breast cancer. Semin Oncol 1988;15(suppl 1):44.
86. Bertomeu MC. Gallo S. Lauri D. et al. Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metastasis 1990; 8:511.
87. Edwards RL. Klaus M. Mathews E. et al. Heparin abolishes the chemotherapy induced increase in plasma fibrinopeptid A levels. Am J Meci 1990:89:25.
88. Rogers JS. Murgo AJ. Fontana JA, Raich PC. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 1988;6:276.
89. Feffer SE, Carmasino LS. Fox RL. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate and 5 floururacil. Cancer 1989;63:1303.
90. Relia C, Coviello M. Giotta F, et al. A prethrombotic state in breast cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 1996:40:151.
91. Canobbio L, Tassio T, Ardizzoni R, et al. Hypercoagulable state induced by cytostatic drugs in stage II breast cancer patients. Cancer 1986;58:1032.
92. von Tempelhoff G-F, Heilmann L. Thrombosis and hemorheol-ogy in patients with breast cancer and adjuvant chemotherapy. Clin Hemorheology 1995:15:311.
93. Wieding JU, OhI C, Fargel M, et al. Antithrombin III bei Pa-tienten mit malignen Erkrankungen. In: Köstering H, eds. Anti-thrombin III Grundlagen, Diagnostik, klinische Bedeutung und Therapie. Stuttgard. New York: Schattauer Verlag, 1984:87.
94. Rutqvist E, Mattson A for the Stockholm Breast Cancer Study Group. Cardiac and thromboembolic morbidity among postmeno-pausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993;85:1298.
95. von Tempelhoff G-F. Niemann F, Schneider D, et al. Blood rhe-ology during chemotherapy in patients with ovarian cancer. Thromb Res 1998;90:73.
96. Auger MJ, Mackie MJ. Effects of tamoxifen on blood coagula-tion. Cancer 1988:61:1316.
97. Lox CD, Ronaghan CA, Cobos E, Messer RH. Tamoxifen-induced changes in the plasma fibrinolytic factors in menopausal women with breast cancer. Clin Appl Thromb Hemost 1997;3:234.
98. Pujol H, Girault J, Rouanet P, et al. Phase I study of percutaneous 4 hydroxy tamoxifen with analyses of 4 hydroxy tamoxifen con-centrations in breast cancer and normal tissue. Cancer Chemother Phannacol 1995;36:493.
99. Powles TJ, Hardy JR. Ashley SE, et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 1989:60:126.
100. Yamamoto H, Noguchi S, Miyauchi K, et al. Changes in héma-tologie parameters during treatment with medroxyprogesterone acetate for breast cancer. Jpn J Cancer Res 1991;82:420.
101. Bonstgnori M, Rossi G, Sturba F, et al. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. Chemioterapia 1986;V:134.
102. Subramaniam S, Subramaniam S, Jagadeesan M, Devi CSS. Al-terations in erythrocyte membrane structure of breast cancer pa-tients treated with CMF-A lipid profile. Chemotherapy 1994; 40:427.
103. Vasigara-Singh W, Subramaniam S, Shyama S, et al. Changes in erythrocyte membrane lipids in breast cancer patients after radio-therapy and chemotherapy. Chemotherapy 1996:42:65.
104. Chahwala SB. Hickmann JA. Effects of the antitumor drug adria-mycin on human blood cell discocyte-echinocyte transitions. Cancer Res 1985:45:4986.
105. Mirshahi SS. Pupde-Lauraine E, Sossia C. et al. D-dimer and Ca 125 levels in patients with ovarian cancer during antineoplastic therapy. Cancer 1992:69:2289.
106. Monreal M. Alastue A, Rull M, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices - prophylaxis with a low molecular weight heparin (Frag-min) Thromb Haemost 1996;75:251.
107. Kakkar AK, Hedges AR. Williamson RCN, Kakkar VV. Periop-erative heparin therapy inhibits late death from metastatic cancer. Im J Oncol 1995:6:885.
108. Lebeau B. Chastang C. Brechot J-M, Capron F. et al. Subcuta-neons heparin treatment increases survival in small cell cancer. Cancer 1994;74:38.
109. Zacharski LR. Henderson WG. Rickles FR, et al. Eftect of dium warfarin on survival in small carcinoma of the lung. JAMA 1981;245:831.
110. Zacharski LR, Costantini V. Blood coagulation activation in cer: challenges for cancer treatment. Haemostaseology 1995:15:14